Companies Kronos Bio, Inc.
Kronos Bio (KRON): executive pay, fiscal 2023
Free brief. Every figure links to the company’s own filing.
Kronos Bio, Inc. no longer files a proxy statement; its last pay data is FY2023.
CEO vs. named peers12th pct.Of 24 peer CEOs
CEO pay, last three years
- $2,796,660FY2022
- $1,761,537FY2023
CEO total pay was $1,761,537 in fiscal 2023, down from $2,796,660 in fiscal 2022.
FY2023: salary $580,000 · bonus $0 · option awards $849,337
Frequently asked questions
Who was the highest-paid executive at Kronos Bio, Inc. in fiscal 2023?
As disclosed, Norbert Bischofberger (President and Chief Executive Officer) was the highest-paid executive at Kronos Bio, Inc. in fiscal 2023, with total compensation of $1,761,537.
How does Kronos Bio, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Norbert Bischofberger's total compensation ranked at the 12th percentile of Kronos Bio, Inc.'s disclosed peer group.
How did shareholders vote on Kronos Bio, Inc.'s executive compensation?
As disclosed, 97.4% of shareholders supported Kronos Bio, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Kronos Bio, Inc. spend in total on board compensation for fiscal 2023?
As disclosed, Kronos Bio, Inc. reported total board compensation of $448,559 for fiscal 2023.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Norbert Bischofberger | $580,000 | $0 | — | $849,337 | $319,000 | $0 | $13,200 | $1,761,537 |
| President and Chief Executive Officer | ||||||||
| Barbara Kosacz | 470,000 | 45,000 | 290,324 | 310,008 | 188,000 | 0 | 3,133 | 1,306,466 |
| Former Chief Operating Officer and General Counsel | ||||||||
| Jorge DiMartino | 475,000 | 27,300 | 286,347 | 305,762 | 190,000 | 0 | 2,275 | 1,286,684 |
| Former Chief Medical Officer and Executive Vice President, Clinical Development | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Norbert Bischofberger | $1,761,537 | $2,796,660 | — | ↓ −1,035,123 |
| Barbara Kosacz | 1,306,466 | — | — | — |
| Jorge DiMartino | 1,286,684 | 1,757,367 | — | ↓ −470,683 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is intended to incentivize the achievement of critical strategic priorities and align executive interests with stockholders. The program aims to attract and retain talented executives, create incentives for long-term stockholder value creation, and differentiate compensation based on individual performance.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer and Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2023
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Norbert Bischofberger | RSU | 2024-02-15 | — | — | 270,339 | — | $291,966 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Norbert Bischofberger | $291,966 | $0 | $0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Norbert Bischofberger | RSU | 14,150 | — | $17,688 |
| Barbara Kosacz | Option | 26,184 | 30.94 | — |
| Barbara Kosacz | RSU | 35,734 | — | 44,668 |
| Jorge DiMartino | RSU | 40,200 | — | 50,250 |
| Barbara Kosacz | RSU | 41,876 | — | 77,350 |
| Barbara Kosacz | Option | 43,334 | 7.08 | — |
| Jorge DiMartino | Option | 48,750 | 7.08 | — |
| Jorge DiMartino | Option | 50,227 | 30.94 | — |
| Norbert Bischofberger | Option | 74,297 | 30.78 | — |
| Jorge DiMartino | RSU | 137,008 | — | 171,260 |
| Barbara Kosacz | RSU | 138,911 | — | 173,639 |
| Jorge DiMartino | Option | 162,698 | 2.09 | — |
| Barbara Kosacz | Option | 164,958 | 2.09 | — |
| Norbert Bischofberger | Option | 216,667 | 7.3 | — |
| Jorge DiMartino | Option | 379,800 | 2.53 | — |
| Norbert Bischofberger | Option | 451,938 | 2.09 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Arie Belldegrun, M.D., FACSIndependent · Not standing for re-election | $82,395 | $0 | $34,802 | — | $0 | $117,197 |
| Katherine Vega StultzIndependent · Not standing for re-election | 36,387 | 0 | 69,288 | — | 0 | 105,675 |
| Roger D. Dansey, M.DIndependent | 29,868 | 0 | 67,647 | — | 0 | 97,515 |
| Elena Ridloff, CFAIndependent · Not standing for re-election | 55,000 | 16,773 | 17,401 | — | 0 | 89,174 |
| Taiyin Yang, Ph.DIndependent | 53,896 | 0 | 34,802 | — | 0 | 88,698 |
| Roshawn BluntIndependent · Not standing for re-election | 45,000 | 0 | 34,802 | — | 0 | 79,802 |
| David M. TanenNot independent · Not standing for re-election | 40,000 | 0 | 34,804 | — | 0 | 74,804 |
| Joshua KazamNot independent · Not standing for re-election | 40,000 | 0 | 34,802 | — | 0 | 74,802 |
| Marianne De Backer, Ph.DIndependent · Not standing for re-election · Departed during FY | 25,240 | 0 | 34,802 | — | 0 | 60,042 |
| Otellla Stampacchia, Ph.DIndependent · Not standing for re-election · Departed during FY | 12,000 | 0 | 0 | — | 0 | 12,000 |
| Otella StampacchiaIndependent | 12,000 | 0 | 0 | — | 0 | 12,000 |
| Norbert Bischofberger, Ph.DEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $335,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $431,786 |
| Equity awards (grant-date value) | $16,773 |
| All other compensation | $0 |
| Total cost of the board | $448,559 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Kronos Bio as a peer
Companies that benchmark against KRON
1 company names KRON as a compensation peer
The list of companies that name KRON as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2023
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
NKTX Nkarta, Inc.CCCC C4 Therapeutics, Inc.MRSN Mersana Therapeutics, Inc.GRTS Gritstone bio, Inc.REPL Replimmune Group, Inc.NRIX Nurix Therapeutics, Inc.GOSS Gossamer Bio, Inc.ITOS iTeos Therapeutics, Inc.SURF Surface Oncology, Inc.VSTM Verastem, Inc.IGMS IGM Biosciences, Inc.ANAB AnaptysBio, Inc.KURA Kura Oncology, Inc.SNDX Syndax Pharmaceuticals, Inc.RAPT RAPT Therapeutics, Inc.ALLO Allogene Therapeutics, Inc.ALXO ALX Oncology Holdings Inc.RUBY Rubius Therapeutics, Inc.JNCE Jounce Therapeutics, Inc.AMAM Ambrx Biopharma Inc.SRRK Scholar Rock Holding CorporationPRLD Prelude Therapeutics, IncorporatedTCRR TCR2 Therapeutics, Inc.RAIN Rain Oncology, Inc.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Scholar Rock Holding Corporation | 2025 | David Hallal | $637,500 | $22,518,500 | $7,624,988 | $452,293 | $33,300,927 |
| 2 | Syndax Pharmaceuticals, Inc. | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 3 | Rapt Therapeutics, Inc. | 2024 | Brian Wong | 630,000 | 0 | 5,927,297 | 416,000 | 6,979,539 |
| 4 | Nurix Therapeutics, Inc. | 2025 | Arthur Sands | 674,584 | 0 | 5,166,196 | 510,000 | 6,374,138 |
| 5 | Allogene Therapeutics, Inc. | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 6 | AnaptysBio, Inc. | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 7 | iTeos Therapeutics, Inc. | 2024 | Michel Detheux | 628,684 | 0 | 4,965,264 | 421,014 | 6,085,657 |
| 8 | Replimmune Group, Inc. | 2026 | Sushil Patel | 700,000 | 3,376,003 | 1,448,325 | 315,000 | 5,845,982 |
| 9 | Kura Oncology, Inc. | 2025 | Troy Wilson | 700,000 | 0 | 3,297,250 | 630,000 | 4,735,016 |
| 10 | IGM Biosciences, Inc. | 2023 | Fred Schwarzer | 646,797 | 868,050 | 1,336,743 | 355,738 | 3,207,328 |
| 11 | Nkarta, Inc. | 2025 | Paul Hastings | 674,384 | 236,250 | 1,711,957 | 344,947 | 2,978,038 |
| 12 | C4 Therapeutics, Inc. | 2025 | Andrew Hirsch | 694,925 | 710,730 | 848,007 | 573,313 | 2,940,975 |
| 13 | ALX Oncology Holdings Inc. | 2025 | Jason Lettmann | 724,500 | 0 | 1,447,488 | 298,856 | 2,470,844 |
| 14 | Verastem, Inc. | 2025 | Daniel Paterson | 674,000 | 1,161,661 | 0 | 489,324 | 2,349,975 |
| 15 | Gossamer Bio, Inc. | 2025 | Faheem Hasnain | 649,649 | 0 | 1,392,006 | 254,800 | 2,300,455 |
| 16 | Kronos Bio, Inc. | 2023 | Norbert Bischofberger | 580,000 | — | 849,337 | 319,000 | 1,761,537 |
| 17 | Mersana Therapeutics, Inc. | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| 18 | Prelude Therapeutics, Incorporated | 2025 | Krishna Vaddi | 615,441 | 0 | 412,744 | 309,465 | 1,348,000 |
| — | Gritstone bio, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Surface Oncology, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Rubius Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Jounce Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Ambrx Biopharma Inc. | — | — | — | — | — | — | not in coverage universe |
| — | TCR2 Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Rain Oncology, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Kronos Bio, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer and Partners, LLC |
| Allogene Therapeutics, Inc. | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| ALX Oncology Holdings Inc. | not disclosed | not disclosed | not disclosed | Compensia |
| Ambrx Biopharma Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| AnaptysBio, Inc. | 110% | not disclosed | No | Alpine Rewards |
| C4 Therapeutics, Inc. | 120% | not disclosed | not disclosed | Pearl Meyer |
| Gossamer Bio, Inc. | 65% | not disclosed | No | Alpine Rewards |
| Gritstone bio, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| IGM Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| iTeos Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Radford |
| Jounce Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Kura Oncology, Inc. | 150% | not disclosed | No | Alpine Rewards |
| Mersana Therapeutics, Inc. | not disclosed | Option 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| Nkarta, Inc. | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Nurix Therapeutics, Inc. | not disclosed | Option 60 · RSU 40 | not disclosed | Aon plc |
| Prelude Therapeutics, Incorporated | not disclosed | Option 100 | not disclosed | Compensia |
| Rain Oncology, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Rapt Therapeutics, Inc. | 120% | Option 100 | not disclosed | Aon plc/Radford |
| Replimmune Group, Inc. | not disclosed | not disclosed | No | Pearl Meyer |
| Rubius Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Scholar Rock Holding Corporation | not disclosed | not disclosed | No | Pay Governance |
| Surface Oncology, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Syndax Pharmaceuticals, Inc. | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| TCR2 Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Verastem, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-06-25 | 26,529,573 | 708,379 | 2,612,452 | 97.4% | Passed |
| 2023 | 2023-06-22 | 26,887,653 | 351,880 | 1,580,283 | 98.71% | Passed |
| 2021 | 2021-06-22 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2024 | 2024-06-25 | 97.4%a |
| 2023 | 2023-06-22 | 98.71%b |
| 2021 | 2021-06-22 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (40 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Norbert Bischofberger. DEF 14A, filed 2024-04-29. Section “2023 Summary Compensation Table” · page 31. As printed: 1,761,537. View filing ↗
- Section 01, Barbara Kosacz. DEF 14A, filed 2024-04-29. Section “2023 Summary Compensation Table” · page 31. As printed: 1,306,466. View filing ↗
- Section 01, Jorge DiMartino. DEF 14A, filed 2024-04-29. Section “2023 Summary Compensation Table” · page 31. As printed: 1,286,684. View filing ↗
- Section 03, Norbert Bischofberger RSU. DEF 14A, filed 2024-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, Arie Belldegrun, M.D., FACS. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 117,197. View filing ↗
- Section 08, Katherine Vega Stultz. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 105,675. View filing ↗
- Section 08, Roger D. Dansey, M.D. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 97,515. View filing ↗
- Section 08, Elena Ridloff, CFA. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 89,174. View filing ↗
- Section 08, Taiyin Yang, Ph.D. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 88,698. View filing ↗
- Section 08, Roshawn Blunt. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 79,802. View filing ↗
- Section 08, David M. Tanen. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 74,804. View filing ↗
- Section 08, Joshua Kazam. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 74,802. View filing ↗
- Section 08, Marianne De Backer, Ph.D. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 60,042. View filing ↗
- Section 08, Otellla Stampacchia, Ph.D. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 12,000. View filing ↗
- Section 08, Otella Stampacchia. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 12,000. View filing ↗
- Section 08, Norbert Bischofberger, Ph.D. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-27. Item 5.07 · say-on-pay result. As reported: 97.4% (votes for as printed: 26,529,573). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-26. Item 5.07 · say-on-pay result. As reported: 98.71% (votes for as printed: 26,887,653). View filing ↗
- Section 06, 2021 vote. Form 8-K, filed 2021-06-24. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 431,786 + equity 16,773 + all other 0 = 448,559, summed across the director compensation table rows.
- Scholar Rock Holding Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Scholar Rock Holding Corporation's own proxy. As printed: 33,300,927. View filing ↗
- Syndax Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Syndax Pharmaceuticals, Inc.'s own proxy. As printed: 7,089,213. View filing ↗
- Rapt Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-14. CEO total compensation as printed in Rapt Therapeutics, Inc.'s own proxy. As printed: 6,979,539. View filing ↗
- Nurix Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Nurix Therapeutics, Inc.'s own proxy. As printed: 6,374,138. View filing ↗
- Allogene Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Allogene Therapeutics, Inc.'s own proxy. As printed: 6,136,093. View filing ↗
- AnaptysBio, Inc., Section 10b CEO total. DEF 14A, filed 2026-06-29. CEO total compensation as printed in AnaptysBio, Inc.'s own proxy. As printed: 6,133,943. View filing ↗
- iTeos Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in iTeos Therapeutics, Inc.'s own proxy. As printed: 6,085,657. View filing ↗
- Replimmune Group, Inc., Section 10b CEO total. DEF 14A, filed 2026-07-29. CEO total compensation as printed in Replimmune Group, Inc.'s own proxy. As printed: 5,845,982. View filing ↗
- Kura Oncology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Kura Oncology, Inc.'s own proxy. As printed: 4,735,016. View filing ↗
- IGM Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in IGM Biosciences, Inc.'s own proxy. As printed: 3,207,328. View filing ↗
- Nkarta, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Nkarta, Inc.'s own proxy. As printed: 2,978,038. View filing ↗
- C4 Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in C4 Therapeutics, Inc.'s own proxy. As printed: 2,940,975. View filing ↗
- ALX Oncology Holdings Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in ALX Oncology Holdings Inc.'s own proxy. As printed: 2,470,844. View filing ↗
- Verastem, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Verastem, Inc.'s own proxy. As printed: 2,349,975. View filing ↗
- Gossamer Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Gossamer Bio, Inc.'s own proxy. As printed: 2,300,455. View filing ↗
- Kronos Bio, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in Kronos Bio, Inc.'s own proxy. As printed: 1,761,537. View filing ↗
- Mersana Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Mersana Therapeutics, Inc.'s own proxy. As printed: 1,613,754. View filing ↗
- Prelude Therapeutics, Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Prelude Therapeutics, Incorporated's own proxy. As printed: 1,348,000. View filing ↗